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BACKGROUND: c Kit (CD117) expression in tissues has been reported as a relevant target for specific therapy in some human
malignancies, but has been poorly documented in breast carcinomas
METHODS: The prognostic significance of c Kit in a series of 924 breast carcinomas (mean follow-up, 79 months) was investigated using
standardised high-throughput quantitative densitometry of immunohistochemical precipitates in tissue microarrays.
RESULTS: c Kit was expressed in 14.7% breast carcinomas (and in 42 out of 586 node-negative tumours). In univariate analysis,
(log-rank test) the score of c Kit expression correlated with poor patient outcome P¼0.02 and particularly in node-negative cases
(P¼0.002). In multivariate Cox analysis, c Kit was an indicator of metastasis independent of 25 other concomitantly evaluated
markers of prognosis. Logistic regression showed that c Kit ranked 10 out of 25 (P¼0.041), and was included in a 10-marker
signature that allowed 79.2% of the patients to be correctly classified in the metastatic or metastasis-free categories independently of
hormone receptors and HER-2 status. Interestingly, c Kit was also a significant predictor of metastasis in node-negative tumours (2 out
of 25 ranking, Po0.0001) and included in a six-marker signature of prognosis, correctly classifying 88.6% of the patients (Po0.0001).
CONCLUSION: We concluded that, as assessed by quantitative immunohistochemistry, c Kit is an independent prognostic indicator that
could also potentially serve as a target for specific therapy in breast carcinomas.
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As a transmembrane tyrosine kinase, c Kit plays a physiological
role in the development of several cell types including haemato-
poietic cells, germ cells and melanocytes (Miettinen and Lasota,
2005). In breast tissue, c Kit is found in normal epithelium and
non-neoplastic breast lesions, suggesting a role in the maintenance
of breast glandular epithelium (Matsuda et al, 1993; Miettinen and
Lasota, 2005).
Published data show a low prevalence of c Kit expression in
breast carcinomas, ranging from 1 to 13% (Tsuura et al, 2002;
Nielsen et al, 2004; Simon et al, 2004; Tsuda et al, 2005; Reis-Filho
and Tutt, 2008), and in one report up to 25% (Tsutsui et al, 2006).
The variations in expression in previous immunohistochemical
studies can be explained by a lack of standardisation of
procedures, particularly of quantification of immunostaining.
Therefore, it is clear that, first, expression of c Kit needs to be
evaluated with a high-throughput standardised procedure in large
series to determine the real prevalence and the clinical relevance of
its identification in individual breast carcinomas. Second, correla-
tion of the levels of c Kit expression with patients’ outcome will
show its actual prognostic value.
In the present immunohistochemical study of 924 invasive
breast carcinomas, we investigated c Kit expression within tissue
microarrays (TMA), quantified by densitometry on digitised
microscopic images using an image analysis device and dedicated
software. The expression of c Kit was correlated with (1) patients’
outcome (mean follow-up, 79 months) and (2) that of 25 other
prognostic markers, with particular attention to node-negative
tumours.
MATERIALS AND METHODS
Patients
The participants were a consecutive series of 1200 patients with
invasive breast carcinomas who were operated on from 1995 to
2002 (mean follow-up, 79 months) in the same department at the
Ho ˆpital Conception, Marseille. Surgery was in all cases the first
treatment (PB). For this first step of treatment, patient manage-
ment was handled by the same group of surgeons and by three
senior pathologists (CC, SG, LA). Conservative treatment, mas-
tectomy and node resection (complete or sentinel) were applied
according to the current European recommendations. Likewise,
radiotherapy, chemotherapy and hormone therapy were applied
according to criteria currently used at that time.
Analysis of the distribution of the series by age, histological type
and grade, and nodal status before TMA construction revealed the
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susual distribution of breast carcinomas and no bias in tumour
selection, as compared with literature data. Owing to the technical
difficulties in carrying out immunocytochemical tests on many
serial paraffin sections of a TMA to evaluate the 35 different
markers (Table 1), complete data for all markers were finally
obtained for only 924 patients out of the initial series of 1200.
The 2005 follow-up data in clinical records showed that 181 out
of 924 patients had metastatic tumours.
Our study focused mainly on correlation of quantitative
immunohistochemical data with patients’ outcome. Current
histoprognostic criteria on H and E staining were not retained
for statistical analysis, mainly to limit the burden of data and also
to focus the statistical analysis on continuous variables homo-
geneously obtained by (numerical) densitometric measurement of
immunoprecipitates with the image analysis device.
Tissue
Tissue samples were all archival material taken from consecutive
surgical specimens after formalin fixation and paraffin embedded
blocks. Attention was paid to optimal consistent tissue-handling
procedures, including fast immersion in buffered formalin in an
appropriate container by pathologists or by nurses trained in the
procedure. Tumour fragments were large (5mm) and thick enough
(3mm) to allow further TMA construction. Duration of fixation
was 24h for smaller samples (o5cm) and 48h for larger ones, to
improve formalin penetration, before specimen dissection at room
temperature. After fixation, paraffin pre-embedding and embed-
ding were carried out with currently available automated devices of
the same brand.
Paraffin blocks were stored in the same room, in which
temperature was maintained at 201C before TMA construction.
TMA construction
The procedure for construction of TMAs was as previously
described (Garcia et al, 2007a,b). Briefly, cores were punched
from the selected 1200 paraffin blocks (from 1200 patients),
distributed in six new blocks including two cores for each tumour
(200 cases per block, a total of 2400 cores) of 0.6-mm diameter. All
the new blocks (TMAs) were stored at 41C, before sections 4-mm
thick were prepared for each marker to be examined by
immunohistochemistry.
Immunohistochemistry
Serial tissue sections were prepared and stored at 41C for 24h
before immunohistochemical processing, as previously reported
(Garcia et al, 2007a,b). Immunoperoxidase procedure was
performed using an automated Ventana Benchmark XT device
and Ventana Kits (Ventana, Strasbourg, Illkirch, France).
Markers were detected using commercially documented
antibodies (Table 1). Dilutions of antibodies were determined by
pre-screening on the usual full 4-mm thick sections before use on
TMA sections.
Image analysis
Automated densitometric measurements of immunoprecipitates in
cores were made for each marker antibody in each core
individually identified after digitisation and image cropping of
the slides, as previously reported (Garcia et al, 2007a,b). Briefly,
TMA analysis with a SAMBA 2050 automated device (SAMBA
Technologies, Meylan/Grenoble and TRIBVN, Chatillon, France)
(Charpin et al, 1997b, 1998a,b, 2004) was carried out according to
the following protocol.
First, an image of the entire slide was built up using low-power
magnification ( 2, pixel dimension 3.7mm). This image was
made up of a mosaic of images acquired along a rectangular grid
with contiguous fields. Second, the area of the slide containing
the TMA cores was automatically delineated and scanned at
higher magnification ( 20, pixel dimension 7.4mm). Third, after
autofocusing, the images were acquired with an overlap greater
than the largest mechanical positioning error. Using the
image contents, a matching algorithm determined precisely the
relative position of each image with respect to its neighbours.
Calculated overlap was removed from images to produce a new
set of higher-magnification images, thus covering precisely the
cores of interest. A specially developed tool referred to as TMA
crop (Plaisir, France) then allowed superposition of the TMA
grid onto the reduced image and precise alignment of each node
of the grid with the core location within the image. The final step
was carried out automatically using the core image contents to
ensure pixel precision of the match. From the images acquired
with  20 magnification, a new set of images was next computed,
one for each core. For colour analysis of the core images, the
SAMBA ‘immuno’ software was applied as previously reported
(Charpin et al, 1994, 1997a,b, 1998a,b,c, 2004; Garcia et al,
2007a,b) in the usual full-tissue sections.
In the present study, we correlated the patients’ follow-up
parameters with a quantitative score combining the surface stained
and the intensity of staining (Garcia et al, 2007a,b) computed by
the SAMBA ‘immuno’ software. The threshold for positive staining
was determined according to a densitometric measurement of c Kit
immunostaining in normal tissue run in the same batch as the
TMAs.
Table 1 Sources of antibodies for immunodetection in tissue micro-
arrays
Antibody Supplier Source Clone
CD117 (c-Kit) Dako Rpab
E-Cadherin Zymed Mmab 4A2C7
CAIX Abcam Rpab
Cytokeratin 903 Dako Mmab 34BE12
P63 Dako Mmab 4A4
FYN Abcam Mmab 1S
SHARP 2 Abcam Rpab
P21Waf1-Cip1 Cell Signaling Mmab DCS60
P27 Kip1 Cell Signaling Rpab
P38 MAP kinase Cell Signaling Rpab
FAK Cell Signaling Rpab
STAT-1 Cell Signaling Mmab 9H2
EGFR Ventana Mmab 3C6
Phospho-MAPKAPK-2 Cell Signaling Rmab (Thr334)
Cytokeratin 19 Dako Mmab BA17
Vimentin Immunotech Mmab V9
CD34 Dako Mmab QBEnd-10
CD10 Novocastra Mmab 56C6
STAT-3 Cell Signaling RMab Tyr 705 D3A7
Cytokeratin 17 Dako Mmab E3
Moesin 1 Biomeda Mmab 38/87
CD44v6 Novocastra Mmab VFF-7
Ezrin(p81,80k,cytovillin) Neomarkers Mmab 3C12
FGFR-1 Flg (C-15) Santa Cruz Rpab
P16 Neomarkers Mmab Ab7(16PO7)
P53 Dako Mmab DO-7
Bcl2 Dako Mmab 124
CD146 Novocastra Mmab N1238
Caveolin 1 Santa Cruz Rpab
c-Met Chemicon/Abcys Mmab 4AT44
JAK 1 Cell Signaling Rpab
Cytokeratins 5-6 Dako Mmab D5/16B4
Abbreviations: Mmab¼mouse monoclonal antibody; Rpab¼rabbit polyclonal
antibody.
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sStatistical analysis
Immunohistochemical expression of each marker was first cor-
related with patients’ disease-free survival using NCSS (www.ncss.
com) and Statistica statistical software (www.statsoft.com).
When significant differences in mean expression were identified
in patients with disease and without disease, the prognostic
significance was determined by log-rank tests (Kaplan–Meier
curves). The appropriate threshold of prognostic significance for
a given marker was determined as previously recommended
(Altman et al, 1994) and described (Charpin et al, 1994, 1997a,b,
1998a,b,c, 2004; Garcia et al, 2007a,b).
Logistic regression (with ROC curves) was then used to
identify the combination of markers with the best sensitivity
and specificity indicative of a proteomic signature of poor
prognosis.
Finally, unsupervised hierarchical clustering of significant
prognostic indicators in the overall series provided qualitative
data to be compared with previously reported research results on
relationships between these molecules, and on the role played by
them in the process of cancer metastasis.
RESULTS
c Kit distribution in node-positive (Nþ) and
node-negative (N ) tumours
The screening of spots by image analyser after TMA ‘cropping’
revealed that 135 (14.7%) of all tumours were c Kit-positive,
whereas among node-negative tumours, 42 out of 584 (7.2%) and
among node-positive tumours 71 out of 340 (21%) were c Kit-
positive.
Positive staining was observed in the cell membrane in normal
breast and also in tumours, as shown in Figure 1.
The mean quantitative score for c Kit, automatically computed
by the image analyser, was significantly higher (P¼0.0007) in
tumours of patients with distant metastasis (m¼12.2, s.d.¼4.3;
n¼181) than in tumours of those lacking distant metastasis
(m¼4.08, s.d.¼1.2; n¼743). Likewise, the mean score was higher
(Po0.0001) in node-positive tumours (m¼6.29; s.d.¼2.11) than
in node-negative tumours (m¼3.47; s.d.¼0.63).
Prognostic value of c Kit in univariate analysis
Comparison of c Kit expression and patients’ outcome using
log-rank tests showed that c Kit was a significant prognostic
indicator in all subgroups (P¼0.02) and in node-negative patients
(P¼0.002) (Figure 2).
A
B
Figure 1 c Kit-positive immunostaining (A) in grade 2 breast carcinoma
and (B) in grade 3 breast carcinomas: ‘spots’ corresponding to tumour
cores measuring 0.6mm in diameter lead to tissue microarray (TMA).
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Figure 2 Kaplan–Meier curve showing significant correlation of c Kit
densitometry and development of distant metastases (mean follow-up
(P¼0.02 and P¼0.002 respectively) 79 months) in (A) 924 breast
carcinoma and (B) 586 node-negative tumours.
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Multivariate Cox analysis showed that c Kit was an independent
prognostic indicator when evaluated with 24 other prognostic indi-
cators categorised as such, using the same quantitative procedure
as that in univariate analysis (log-rank test, Po0.01), in the whole
series of 924 tumours and in the 584 node-negative tumours.
Hierarchical unsupervised clustering (Figure 3) showed the
relationship of c Kit with the other markers, independently of
hormone receptor and HER-2 status.
To determine the prognostic value, the ranking of c Kit was
compared with that of 25 other markers in logistic regression in
the series of 924 patients and in the 584 node-negative tumours,
independently of ER, PR and HER-2 expression (Tables 2 and 3,
Figures 4–7).
The first step of logistic regression in the series of 924 tumours
showed that 10 out of the 25 markers tested allowed correct
classification of 81.17% patients in both categories of good and
poor prognosis (sensitivity 78.5%, specificity 92.3%, area under
ROC curve 0.906), as shown in Figure 4, and the ranking of c Kit,
based on odds ratio and P-value of deviance increase (P¼0.012),
was 10 out of 25 (Table 2).
When a second regression step was assessed with the significant
markers from the first step, including c Kit, the results showed that
a slightly lower percentage of patients (79.22%) were well classified
(sensitivity 75.9%, specificity 92.8%, area under ROC curve
0.89) (Figure 5), as compared with the first regression step
(81.17%). All 10 markers including c Kit remained highly
significant for prognostic prediction of metastasis (P-value of
deviance increase¼0.0411).
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Figure 3 Unsupervised hierarchical clustering of 25 (individually prognostic significant often log-rank tests) markers evaluated by quantitative
immunohistochemical (image analysis/densitometry) expression, on tissue microarray (TMA) in (A) 924 breast carcinomas and (B) 586 node-negative
carcinomas.
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considered, the first-step regression showed that c Kit ranked
second among the six-marker signature (Table 3) that correctly
classified 80.95% of the patients (sensitivity 80.4%, specificity
83.8%, area under ROC curve 0.960) (Figure 6) in the metastatic or
metastasis-free subsets. Moreover, c Kit remained very prognos-
tically significant (Po0.0001) along with six others. The ranking of
c Kit was 2 out of 25, based on odd ratios and P-values of deviance
increase (Table 3).
Finally, when a second step of regression was carried out in this
node-negative subset with only the six most prognostically
significant markers out of 25, patients were well classified in
88.6% (sensitivity 90.3%, specificity 86.5%; area under ROC curve
0.96; Figure 7) and c Kit remained clearly a prognostic predictor
and still ranked 2 out of 6.
DISCUSSION
Breast cancer is a heterogeneous disease, encompassing a number
of distinct biological entities that are associated with specific
Table 2 Logistic regression of 25 immunohistochemical markers
(quantitative score from image analysis) in tissue microarrays of 924 breast
carcinomas
Marker Odds ratio P-value of deviance increase
1 Moes 0.6939 0.0000
2 P53 0.4091 0.0000
3 pMAPK 1.4654 0.0000
4 P38 07979 0.0026
5 CaIX 1.1941 0.0041
6 CD44v6 1.1866 0.0071
7 CK903 0.8573 0.0191
8 P21 0.8577 0.0249
9 CAVEOL 0.7986 0.0322
10 c kit 0.8816 0.0411
11 CK5-6 1.1262 0.0654
12 JAK 1.1110 0.0711
13 K8-18 0.8925 0.0864
14 P16 0.9078 0.1292
15 EGFR 1.1024 0.1392
16 K14 1.1062 0.1471
17 CD34 0.9292 0.2282
18 P63 1.0754 0.3291
19 FAK 0.9400 0.3666
20 PSTAT3 0.9471 0.4750
21 Bcl2 1.0452 0.4968
22 CK19 1.0413 0.5140
23 Ezrin 0.9648 0.5737
24 FgFR1 0.9792 0.7484
25 CK17 0.9999 0.9982
Bold digits signify markers found to be prognostically significant.
Table 3 Logistic regression of 25 immunohistochemical markers
(quantitative score from image analysis) in tissue microarrays of 586
node-negative breast carcinomas
Markers Odds ratio P-value of deviance increase
1 P53 0.3290 o0.0000
2 c kit 0.6190 o0.0000
3 P21 0.6190 0.0001
4 CK903 0.7331 0.0082
5 Moes 0.7369 0.0204
6 CK17 1.3529 0.0217
7 EGFR 1.2385 0.0553
8 CD44V6 1.3099 0.0609
9 Bcl2 1.2337 0.0679
10 P38 1.2730 0.0793
11 pMAPK 1.2851 0.0889
12 JAK 1.1817 0.1144
13 FgFR1 0.8399 0.1194
14 P16 1.2008 0.1495
15 CaIX 1.1726 0.1766
16 CK8-18 1.1561 0.2086
17 FAK 0.8568 0.2249
18 Ezrin 1.0852 0.4662
19 P63 1.0564 0.6560
20 CK14 1.0375 0.7727
21 PSTAT3 1.0262 0.8695
22 CK19 1.0157 0.8876
23 KER56 1.0121 0.9157
24 CAVEOL 1.0286 0.9223
25 CD34 0.9908 0.9341
Bold digits signify markers found to be prognostically significant.
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Figure 4 ROC curves after logistic regression of quantitative immuno-
histochemical expression of 25 prognostic markers in breast carcinomas on
tissue microarray (TMA): in whole series (n¼924) (81.17% of well-
classified patients), first step of regression.
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Figure 5 ROC curves after logistic regression of quantitative immuno-
histochemical expression of 25 prognostic markers in breast carcinomas on
tissue microarray (TMA): second step of regression (79.22% of well-
classified patients).
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smorphological and immunohistochemical features and clinical
behaviour (Simpson et al, 2005). Despite this morphological
heterogeneity, however, patients can practically be classified into
three main groups for management and therapy according to: (1)
hormone receptor (ER, PR) positivity, (2) presence of Her-2 neu
(c-erb B2) amplification or (3) absence of these two characteristics.
In the latter group of patients lacking specific targets for hormone
and trastuzumab therapy, there is a need to identify new targets for
tailored treatments. Genome microarray analysis (Perou et al,
2000; Sorlie et al, 2003) and expression profiling (Reis-Filho et al,
2006) have recently been used to characterise five groups of breast
cancers that can also be identified by immunohistochemical
screening. In particular, for the triple-negative (ER-PgR-HER-
negative) tumours, this deeper molecular insight into tumour
characterisation should allow new targets for tailored therapies to
be identified. In this regard, the inhibition of c Kit gene expression
by imatinib (STI 571, Glivec), which was initially shown to be
effective in the treatment of chronic myeloid leukaemia (Kantar-
jian et al, 2002), has more recently been found effective also
against c Kit-positive gastrointestinal stroma tumours (GIST)
(Miettinen et al, 2001), suggesting that other c Kit-positive
tumours, in particular breast carcinomas, may respond to imatinib
therapy.
In breast cancer, expression of c Kit is reported to be reduced
and detected in 1–13% of tumours (Tsuura et al, 2002; Nielsen
et al, 2004; Simon et al, 2004; Tsuda et al, 2005; Reis-Filho and
Tutt, 2008). Our results are close to the upper range of previous
reports, with 14.7% of positive tumours in our series. However,
some conflicting results have also recently been reported showing
a decrease of cKit expression in advanced stage and poor
prognosis in breast cancer (Tsutsui et al, 2006). The variations
in the literature data probably result from the diversity of
immunodetection procedures used and also from the lack of
results quantification. In this respect, automated quantification
of immunoreactions in sections of hundreds of 0.6-micron-thick
micro-biopsy cores, using dedicated software to measure extents
of staining by densitometry after ‘cropping’ on digitised micro-
scopic images of immunostained TMA, provides a time- and
cost-effective, reproducible and accurate means of evaluation,
particularly in comparison with approximate and subjective
semi-quantitative methods.
Literature data show that c Kit expression in breast cancer is
more common in basal-like carcinomas (31%), medullary (19%),
grade 3 (24%) and metaplastic (57%) carcinomas (Nielsen et al,
2004; Reis-Filho and Tutt, 2008). In our study, c Kit staining was
also found to be significantly more highly expressed in more
aggressive, node-positive tumours than in node-negative carcino-
mas (results not shown).
Our results show that c Kit is part of an immunohistochemical
signature that permits correct classification of 81.17% patients in
the metastatic or metastasis-free categories (mean follow-up 79
months), and 80.95% of node-negative patients. Patients could
thus be selected for more aggressive therapy according to evidence
from analysis of this immunohistochemical signature at the time of
diagnosis, which can be carried out with only a small amount of
fixed and paraffin-embedded tissue (7 to 10 4-micron-thick tissue
sections) remaining in blocks after microscopic diagnosis and pTN
staging. Moreover, this procedure is significantly less time-
consuming, as well as cheaper to carry out, than molecular
(genome and transcriptome) profiling, so that the results can be
available within the same timescale as the pathological report.
Thus, standardised quantification of this immunohistochemical
signature including cKit (using automated image analysis) could
be suitable to examine individual tumours in routine clinico-
pathological practice, in both node-positive and -negative breast
cancers.
Likewise, the prognostic significance of c Kit expression in
tumours, in conjunction with the other markers of the signature
established by logistic regression, may allow selection of patients
for more aggressive therapy, particularly with node-negative
tumours. Also, c Kit expressed in the 14.7% of tumours (included
in our series) that were positive may serve as a target for specific
therapy with imatinib. However, in contrast to GIST, for which
imatinib has proved to be an efficient tailored therapy, experience
with imatinib therapy in breast cancer is limited. A trial conducted
by Modi et al (2005) did not establish clinical benefit. However, in
that study, no c Kit expression was detected in 8 out of the 11
patients enroled with available tissue. In another pilot study, 9 out
of 10 patients enroled with moderate expression of cKit in tumours
were partially responsive to imatinib associated with aromatase
inhibitors (Chow et al, 2008).
In GIST, accumulation of c Kit is usually related to activating
mutations. In breast cancer, no mutation has so far been found,
though reports referred to very short patient series (n¼10)
(Simon et al, 2004). The relationships of c Kit expression and
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Figure 6 ROC curves after logistic regression of quantitative immuno-
histochemical expression of 25 prognostic markers in breast carcinomas on
tissue microarray (TMA): in node-negative carcinomas (n¼586) first step
(80.95% of well-classified patients).
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Figure 7 ROC curves after logistic regression of quantitative immuno-
histochemical expression of 25 prognostic markers in breast carcinomas on
tissue microarray (TMA): second step (88.6% of well-classified patients).
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smutations, and patients’ response to imatinib-tailored therapy
deserve further investigation in conjunction with clinical trials to
gain deeper insight into pathways of c Kit regulation and signalling
in breast cancer.
In conclusion, our study shows that, as assessed with our high-
throughput quantitative immunohistochemical procedure in
TMAs from 924 breast cancers, c Kit was expressed in 14.7% of
patients and was predictive of patients’ outcome, and also in node-
negative subsets. Evaluation of c Kit concomitantly with 10 or 6
other prognostic markers by the same method provides a cost-
effective procedure permitting the correct classification of 81.17–
88.6% of the patients into the metastatic and metastasis-free
categories, independent of hormone receptor and HER-2 status,
and may be useful in selecting node-negative patients for more
aggressive therapy. Finally, for tumours expressing cKit, patients
should potentially benefit from tailored therapy with imatinib, in a
similar manner to the use of trastuzumab to treat tumours that
strongly overexpress HER-2. However, deeper insight into the
mechanisms of c Kit downregulation and clinical trials are
required to show the relevance of this tailored therapy in breast
cancer, as seen with other malignancies such as GIST.
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